Drug Database
PI

piperacillin (piperacillin, KRKA / Isipen)

✓ Approved

Krka · Small Molecule · Small Molecule

What is piperacillin?

piperacillin is a small molecule developed by Krka. It is approved for therapeutic indications via unknown.

Drug Profile

Brand Namespiperacillin, KRKA, Isipen
CompanyKrka
Drug ClassSmall Molecule
RouteUnknown
StatusApproved
Sources: ClinicalTrials.gov, Krka

Therapeutic Indications

piperacillin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsSalmonellosis✓ Approved

Related Research Articles

PubMedFrontiers in medicine2026-11-11

An asymptomatic pulmonary arteriovenous fistula presenting with a Campylobacter rectus brain abscess as the initial manifestation: a case report.

Li Jiarong J, Ji Xinxin X, Zhang Huanming H, Liao Yu Y et al.

Brain abscess is a severe infectious disease of the central nervous system associated with high rates of mortality and morbidity. Pulmonary arteriovenous fistula (PAVF) is a rare but important cause of cryptogenic brain abscesses. The pathogens associated with PAVF-related brain abscesses are typically oral anaerobes or facultative anaerobes, most commonly non-hemolytic streptococci and Streptococcus intermedius. To our knowledge, no case of a monomicrobial Campylobacter rectus (C. rectus) brain abscess in a patient with asymptomatic PAVF has been reported. Herein, we report the case of a 57-year-old man with a C. rectus brain abscess in association with an asymptomatic PAVF. The patient presented to our hospital with fever and headache. Magnetic resonance (MR) imaging revealed a 5 × 2 cm brain abscess in the right temporal and occipital lobes, surrounded by extensive edema. Enhanced computed tomography (CT) scanning of the lungs revealed both nodules and PAVF. Blood culture and cardiac ultrasound failed to detect any abnormalities. Piperacillin-tazobactam and meropenem were administered for anti-infection, although the headache persisted. He was subsequently transferred to neurosurgery to resect the abscess by craniotomy; postoperative pus culture confirmed the presence of C. rectus. For brain abscesses caused by oral anaerobes such as C. rectus, screening for right-to-left shunting diseases such as PAVF may be considered when no other source is identified.

PMID 43010895
Read full article →
PubMedThe Journal of antimicrobial chemotherapy2026-11-10

Real-world outcomes of Citrobacter freundii, Klebsiella aerogenes, and Enterobacter cloacae bacteremia treatment (ROCKET): a contemporary analysis of treatment strategies.

Jawanda Jasanjeet J, Shields Ryan K RK, Balasubramani G K GK, Clarke Lloyd L et al.

To determine comparative effectiveness of piperacillin/tazobactam and cefepime for the treatment of bacteremia due to Enterobacterales at moderate risk for clinically significant AmpC production. A retrospective multicentre study was conducted among adults with bacteremia due to Enterobacter cloacae complex, Klebsiella aerogenes, or Citrobacter freundii complex from 2017 to 2025. Treatment-emergent resistance was defined as a ≥4-fold MIC increase or a categorical change in susceptibility within 90 days. Seven hundred twenty-eight patients met inclusion criteria. The median (IQR) age was 67 years (55-74), and 35% (252/728) were immunocompromised. Cefepime was used for definitive therapy in 47% (342/728), followed by piperacillin/tazobactam in 18% (129/728) and carbapenems in 16% (115/728). Overall, 30-day mortality was 12% (88/728). Patients receiving piperacillin/tazobactam had a higher median (IQR) Pitt bacteremia score (2 [1-3] versus 1 [0-3], P=0.017) than those receiving cefepime, but rates of 30-day mortality (14% [18/129] versus 11% [37/342], P = 0.345) and relapsed infection between days 5-14 (3% [4/129] versus 2% [5/342], P = 0.266) were similar. After inverse probability of treatment weighting, 30-day mortality rates between patients treated with piperacillin/tazobactam and cefepime were not significantly different (HR 1.05, 95% CI 0.57-1.92). Treatment-emergent resistance to definitive therapy occurred in 1% (5/342), 2% (3/129), and 3% (4/115) of patients treated with cefepime, piperacillin/tazobactam, and carbapenems, respectively. In the largest study to date of bacteremia due to E. cloacae complex, K. aerogenes, or C. freundii complex, treatment-emergent resistance was uncommon, and outcomes did not differ significantly between patients treated with piperacillin/tazobactam and cefepime.

PMID 43004943
Read full article →
PubMedMilitary medicine2026-11-10

A Case Report of Severe Leptospirosis After a Rat Bite in an Urban Setting.

Chameli Thomas C TC, Mitre Edward E, Ganesan Anuradha A, Everson Kyle A KA

A 21-year-old healthy male presented with a sepsis syndrome approximately 17 days after a wild urban rat bite. In the emergency room, he was initiated on piperacillin-tazobactam, and after receipt of the first dose, he developed worsening tachycardia, rigors, and hypoxia, followed by hypotension. Given the rodent exposure, the medical team suspected leptospirosis and attributed his decline to a Jarisch-Herxheimer (JH) reaction. A BioFire Global Fever Special Pathogens Panel was obtained the morning after admission and was positive for Leptospira DNA. A CDC lipL32 nucleic acid amplification test from admission was also positive, as was the microscopic agglutination testing (MAT) at 5 weeks. Notably, admission IgM and MAT results were negative. The patient received a 7-day course of ceftriaxone with resolution of most of his symptoms. Leptospirosis is a zoonotic infection typically acquired via exposure to water contaminated with the urine of infected animals, most commonly rodents. This case of severe leptospirosis contributes to the growing literature on leptospirosis occurring in association with rat bites and demonstrates that clinical suspicion combined with nucleic acid testing early in the disease course can enable rapid diagnosis.

PMID 43007297
Read full article →
PubMedEuropean journal of pediatrics2026-11-10

Clinical recommendations for the inpatient management of lower respiratory tract infections in children and adolescents with severe neurological impairment in Germany-2026 Update.

Mauritz Maximilian David MD, von Both Ulrich U, Dohna-Schwake Christian C, Gille Christian C et al.

Children and adolescents with severe neurological impairment (SNI) require specialized care due to their complex medical needs. These patients often experience severe, recurrent lower respiratory tract infections (LRTIs). These infections, of both viral and bacterial etiology, pose a significant risk to these patients, often resulting in respiratory insufficiency and long-term impairments. Based on expert consensus and newly available data, we have updated the previous 2024 clinical recommendations on the management of LRTIs in children and adolescents with SNI in Germany. This update now also addresses multidrug-resistant organism colonization, respiratory support, discharge planning, and prophylactic strategies. The recommendations emphasize comprehensive multidisciplinary care, antimicrobial stewardship, and a stepwise, risk-stratified approach to antibiotic therapy. Initial treatment should involve symptomatic care, including hydration, antipyretics, oxygen therapy, secretion management, and respiratory as well as cough support. In suspected bacterial LRTIs, antibiotic treatment (ABT) should be guided by clinical severity, previous microbiological findings, and treatment response, with an aminopenicillin plus a beta-lactamase inhibitor recommended for community-acquired LRTIs and piperacillin-tazobactam reserved for selected high-risk patients. Ongoing management includes regular reassessment, adjustment of ABT based on pathogen identification, and optimization of supportive care.Conclusion: The updated recommendations provide a practical, multidisciplinary framework for the inpatient management of LRTIs in children and adolescents with SNI, combining optimized supportive care with antimicrobial stewardship and a stepwise, risk-stratified approach to antibiotic treatment. What is Known: • Children and adolescents with severe neurological impairment are particularly affected by severe and recurrent lower respiratory tract infections (LRTI) • The indication and choice of antibiotic therapy for bacterial LRTI is often difficult because there are no evidence-based treatment recommendations for this heterogeneous but vulnerable patient population • The frequent overuse of broad-spectrum or reserve antibiotics in this patient population increases selection pressure for multidrug-resistant pathogens What is New: • Compared with the 2024 recommendations, this update provides more detailed guidance on secretion management and respiratory and cough support, introduces explicit discharge criteria, and expands decision-making for patients colonized with multidrug-resistant organisms. The antibiotic strategy has been further specified regarding broad-spectrum antibiotic therapy, while preventive recommendations have been expanded and updated.

PMID 43003928
Read full article →
PubMedBMC pediatrics2026-11-09

Probable primary bloodstream infection caused by multidrug-resistant Achromobacter piechaudii in an apparently immunocompetent child: a case report.

Xiang Yunfeng Y, Duan Ling L, Xiong Daoxue D, Liu Xiangjun X

Achromobacter piechaudii is an extremely rare opportunistic pathogen in humans. Previous reports of clinical infection have mostly involved adults with underlying conditions such as malignancies or immunocompromised states.This report describes the probable first case of primary, multidrug-resistant Achromobacter piechaudii bloodstream infection in an apparently immunocompetent child. A previously healthy 10-year-10-month-old boy with no known immunodeficiency or chronic disease was admitted with intermittent headache and fever for 4 days, accompanied by chills, vomiting, and lethargy.He had no recent travel, sick contacts, or known exposure to contaminated water. Complete blood count showed elevated white blood cell count and neutrophil percentage. C-reactive protein and procalcitonin were markedly elevated. Empirical treatment with ceftriaxone was started on admission. On day 2 of hospitalization, blood culture indicated growth of Gram-negative bacilli. On day 3, the isolate was identified as Achromobacter piechaudii by MALDI-TOF MS (score > 2.3). Cerebrospinal fluid examination was normal, confirming primary bloodstream infection. Antimicrobial susceptibility testing showed a multidrug-resistant phenotype. The antibiotic regimen was switched to piperacillin-tazobactam after resistance to ceftriaxone was confirmed.The patient's fever resolved, clinical symptoms disappeared, and the outcome was favorable. To our knowledge, this is the probable first case report of primary multidrug-resistant Achromobacter piechaudii bloodstream infection in an apparently immunocompetent child.This case suggests that clinicians should consider rare Achromobacter species when managing pediatric bloodstream infection without obvious immunodeficiency. The multidrug-resistant phenotype highlights the need for accurate species identification and susceptibility-guided therapy.

PMID 43000288
Read full article →
PubMedIDCases2026-11-09

Cervicofacial necrotizing fasciitis: A complication of otitis externa.

Ben Aissa Mariem M, Khbou Amin A, Meherzi Samia S, Benkrikch Ferdaous F

Cervicofacial necrotizing fasciitis (CNF) is a rare, rapidly progressive and life-threatening soft-tissue infection. Otogenic sources are uncommon, and extension from the external auditory canal (EAC) to the adjacent facial and temporal soft tissues may be difficult to recognize, particularly in patients with diabetes. We report a 62-year-old man with diabetes mellitus, hypertension and dyslipidaemia who presented in July 2025 with a severe right otologic infection and rapidly progressive temporofacial and retroauricular soft-tissue necrosis. He had a one-month history of otalgia and otorrhoea, with marked clinical deterioration during the six days preceding admission. Examination revealed fever (39 °C), severe hyperglycaemia (4 g/L), a stenotic purulent external auditory canal, and a right House-Brackmann grade III facial nerve palsy. CT demonstrated extensive right temporo-occipital soft-tissue infiltration extending to the external auditory canal, tympanic cavity and posterior mastoid air cells, with tympanic bone erosion but no intracranial extension. Pseudomonas aeruginosa was isolated from EAC cultures. Urgent surgical exploration revealed extensive necrosis of the subcutaneous tissues and fascia, with complete necrosis of the auricle requiring total auriculectomy. Repeated debridement, culture-directed piperacillin-tazobactam and intensive wound care achieved local control. The wound healed completely during six months of follow-up, although facial nerve function remained HB grade III. The patient was subsequently transferred to another city for reconstructive surgery, and the outcome of reconstruction was unavailable. This case illustrates an uncommon otogenic presentation of CNF with extensive auricular and temporofacial soft-tissue necrosis. In a high-risk diabetic patient, persistent otorrhoea, EAC granulation, facial palsy and rapidly progressive periauricular inflammation should prompt early consideration of a severe necrotizing infection and urgent surgical assessment.

PMID 43001196
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about piperacillin